Increasing IL-2 signaling has been postulated as a possible therapy for UC/CMML patients since it may increase Treg populations and increase NK cell activity, leading to increased protection of colonic mucosa in UC and increased cytotoxicity directed to tumor cells in CMML [24,25]. The gene discussed is IL2; the disease is neoplasm.